Kevin D Bunker Net Worth & Insider Trades
Kevin D Bunker - Chief Scientific Officer, Zentalis Pharmaceuticals, Inc
What is Kevin D Bunker's Net Worth?
The current estimated net worth of Zentalis Pharmaceuticals, Inc's Chief Scientific Officer, Kevin D Bunker, is estimated to be about $33.25M . Kevin D Bunker owns about 95,350 units of Zentalis Pharmaceuticals, Inc common stock. In the last 2 years at Zentalis Pharmaceuticals, Inc, Kevin D Bunker has sold an estimated value of $18.04M worth.
What is Kevin D Bunker's Past Insider Trading?
Kevin D Bunker's largest purchase order was 101,395 units , worth over $6.3K on November 25, 2020. Kevin D Bunker's largest sale order was 36,587 units , worth over $1.82M on January 6, 2021. In total, Kevin D Bunker has made about 36 transactions over 2 years of their time at Zentalis Pharmaceuticals, Inc. Kevin D Bunker usually trades in April, March and July, with the busiest year in 2021. The most recent transaction was a sale order of 5,000 units , worth over $150K on August 12, 2022.
Kevin D Bunker
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
What was Kevin D Bunker's Salary in 2020?
As Chief Scientific Officer of Zentalis Pharmaceuticals, Inc, Kevin D Bunker has a total base salary of $428,771 . Kevin D Bunker received compensation valued at about $6,273,594 in 2020 after becoming Chief Scientific Officer. The vast majority of their compensation came in the form of stock awards of $2,580,864 , option awards of $2,993,235 , other earnings, plans or compensations of $179,550 , and other compensation of $91,174 .
What is Kevin D Bunker's' Mailing Address?
- Mailing address is C/o Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018 NY
Zentalis Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
---|---|---|---|---|---|---|---|---|
Anthony Sun, M.D. | 2020 | $561,232 | - | $8,100,645 | $5,986,469 | $287,375 | $108,678 | $15,044,399 |
Anthony Sun, M.D. | 2019 | $455,091 | - | - | $918,000 | $204,971 | - | $1,577,882 |
Kevin Bunker, Ph.D. | 2020 | $428,771 | - | $2,580,864 | $2,993,235 | $179,550 | $91,174 | $6,273,594 |
Kevin Bunker, Ph.D. | 2019 | $360,024 | - | - | $275,400 | $144,010 | - | $779,434 |
Alexis M. Pinto | 2020 | $136,923 | - | - | $6,234,468 | $152,000 | $10,511 | $6,533,902 |
No matching records found |
Source: https://www.sec.gov/Archives/edgar/data/1725160/000172516021000099/proxystatement-2021.htm
What are Zentalis Pharmaceuticals, Inc's Past Insider Trades?
Zentalis Pharmaceuticals, Inc's most recent insider trade came on January 18, 2023 by Cam Gallagher who sold 10,000 units worth $241.51K . In the last 3 years, insiders at Zentalis Pharmaceuticals, Inc have sold an estimated value of $107.24M and bought an estimated value of $15.77M worth of shares. Insider trading is most common in February, with the busiest year in 2021. The most active traders at the company are Cam Gallagher, President, Kevin D Bunker, Chief Scientific Officer, and Anthony ySun, President & CEO .
Zentalis Pharmaceuticals, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |